67 WALL STREET, New York - December 28, 2012 - The Wall Street Transcript has just published its Best Biotechnology and Pharmaceutical Investing Interviews of 2012 Report offering a timely review of the sector to serious investors and industry executives. This special feature contains expert industry commentary through in-depth interviews with public company CEOs, Equity Analysts and Money Managers. The full issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online.
Topics covered: Biotechnology and Pharmaceutical Investing
Companies include: Celgene Corporation (CELG), Gilead Sciences Inc. (GILD), Regeneron Pharmaceuticals Inc. (REGN), Onyx Pharmaceuticals Inc. (ONXX), United Therapeutics Corp. (UTHR), Ariad Pharmaceuticals Inc. (ARIA), Synta Pharmaceuticals Corp. (SNTA), Rigel Pharmaceuticals, Inc. (RIGL), Isis Pharmaceuticals, Inc. (ISIS) and many others.
In the following excerpt from the Best Biotechnology and Pharmaceutical Investing Interviews of 2012 Report, a leading equity research analyst his valuation methods and top stock picks for these sectors for investors:
TWST: You prefer U.S. biotech stocks relative to U.S. pharma stocks. Please tell us your reasons for that view.
Dr. Birchenough: If you look over the last several years, the valuations for U.S. biotech stocks have contracted substantially, where if we look at valuation relative to forward earnings, the valuations are pretty close between U.S. biotech and U.S. pharma. But with U.S. biotech, what you get that you don't get with U.S. pharma is a more sustainable growth pattern for legacy products. We don't see the patent cliffs that we see for large pharma, you see better pricing power outside the U.S. and bigger opportunities for international growth, and we think you see a greater degree of innovation, which ultimately is what drives value. And the bottom line is we think there are higher barriers to entry that are established by large U.S. biotech companies than we see with large pharma.
TWST: What are some of the most exciting new drugs or technologies coming out of your companies investors would want to be aware of?
Dr. Birchenough: I think the biggest things thematically that we're seeing from a technology perspective is continued focus on molecular diagnostics guiding molecular therapeutics in oncology, in particular. And so what we're starting to see is companies succeeding at identifying key drivers of cancer-cell growth, identifying with diagnostics what those drivers are, and targeting those patients specifically with highly effective drugs. This is an area that we think we're going to continue to see growth in and where most of the oncology studies that are starting right now are being done with molecular diagnostics and better-characterized patients and more targeted drugs targeted at these oncogenic drivers of disease...
For more of this interview and many others visit the Wall Street Transcript - a unique service for investors and industry researchers - providing fresh commentary and insight through verbatim interviews with CEOs, portfolio managers and research analysts. This special issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online.